Spero Therapeutics Inc

Insider sell‑to‑cover at Spero Therapeutics shows no strategic shift—focus on clinical milestones, liquidity, and MDR antibiotic prospects drives investor insight.

Insightful analysis of Spero Therapeutics’ insider buying, MDR antibiotic platform, and market dynamics—why executives are bullish and what investors should watch.

CEO’s RSU purchase shows confidence in Spero Therapeutics’ antibacterial pipeline and upcoming clinical milestones.